# Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults

> **NCT00259831** · PHASE3 · COMPLETED · sponsor: **CV Technologies** · enrollment: 500 (—)

## Conditions studied

- Upper Respiratory Infection

## Interventions

- **DRUG:** CVT-E002 (Cold-FX); a natural health product

## Key facts

- **NCT ID:** NCT00259831
- **Lead sponsor:** CV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-06
- **Final completion:** 2006-08
- **Target enrollment:** 500 (—)
- **Last updated:** 2009-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259831, "Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00259831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*